Mei-Lin Ah-See

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo et al. · Journal of Clinical Oncology · 2022 · 475 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · Journal of Clinical Oncology · 2018 · 70 citations

Medicine, Oncology, Pharmacotherapy +17

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Yvette Drew, Jae‐Weon Kim, Richard T. Penson et al. · Clinical Cancer Research · 2023 · 70 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer

Michael Kosmin, Andreas Makris, Priya V. Joshi et al. · European Journal of Cancer · 2017 · 49 citations

Medicine, Oncology, Radiology +12